Search
Talimogene laherparepvec
go.drugbank.com/drugs/DB13896ApprovedInvestigationalIt was approved by the FDA in 2015 under the market name Imlygic. In general, talimogene laherparepvec has been modified so that it can infect and multiply inside melanoma cells [L2221].
Brinzolamide
go.drugbank.com/drugs/DB01194Approved[A2051] Brinzolamide was approved by the FDA in 1998 as a standalone product and in 2013 as a combination product with brimonidine tartrate.
Aripiprazole lauroxil
go.drugbank.com/drugs/DB14185ApprovedAripiprazole lauroxil was initially approved by the FDA in October 2015 under the market name Aristada for the treatment of schizophrenia. … It is administered via intramuscular injection, and requires the establishment of tolerability prior to dosing in treatment-naïve patients [FDA Label].
Ulipristal
go.drugbank.com/drugs/DB08867ApprovedInvestigationalUlipristal is a selective progesterone receptor modulator used for the purposes of emergency contraception (Ella) and for the treatment of uterine fibroids (Fibristal). It is a derivative of 19-norprogesterone and has both antagonistic a...
Azacitidine
go.drugbank.com/drugs/DB00928ApprovedInvestigationalIn January 2007, the FDA approved the intravenous administration of azacitidine. … [A1415] The use of oral azacitidine for the treatment of AML in patients in complete remission was approved by the FDA in September 2020.[L35335]
Natalizumab
go.drugbank.com/drugs/DB00108ApprovedInvestigationalIn 2006, the FDA reintroduced the drug to the market for multiple sclerosis.[A261326] Natalizumab was further approved by the FDA for the treatment of Crohn's Disease in January 2008. … [A261331] On August 24, 2023, the first biosimilar to natalizumab, natalizumab-sztn, was approved by the FDA.[L48041] Natalizumab was approved by the European Commission on September 22, 2023.
Tozinameran
go.drugbank.com/drugs/DB15696ApprovedInvestigationalFDA on July 13, 2020. … [L26996] Full FDA approval was granted on August 23, 2021.
Dacomitinib
go.drugbank.com/drugs/DB11963ApprovedInvestigational[A40009] Dacomitinib was developed by Pfizer Inc and approved by the FDA on September 27, 2018.
Vepdegestrant
go.drugbank.com/drugs/DB19006ApprovedInvestigational[A275508, A275509] On May 1, 2026, the FDA granted approval for vepdegestrant tablets under the trade name VEPPANU.
Adalimumab
go.drugbank.com/drugs/DB00051ApprovedInvestigationalAdalimumab-atto was the first adalimumab biosimilar approved by the FDA in 2016.[L44953] Adalimumab-adaz was approved by the FDA on October 31, 2018. … [A39984,A39999] It was originally launched by Abbvie in the U.S. and approved in 2002 by the FDA.[A39983] This drug is frequently known as _Humira_.